RevealAI-Lung’s machine learning searches characteristics from numerous patients to produce new biomarkers. Credit: Gerd Altmann from Pixabay.

Mindshare Medical, a clinical decision support technologies developer, has received the European CE-Mark for the use of its RevealAI-Lung solution with computed tomography (CT) scans.

Backed by artificial intelligence (AI) technology, RevealAI-Lung is a computer assisted diagnostic (CADx) software meant for the diagnosis of lung cancer. It reveals patterns within lung CT scan images and across patients by leveraging analytics integrated within the clinical workflow.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

These analytics create actionable scores for the patient through comparison of abnormalities to people with a confirmed diagnosis.

RevealAI-Lung’s machine learning searches characteristics from numerous patients to produce new biomarkers and displays the results in graphs, offering instant feedback on the patient’s population context.

This information is said to assist in follow-up for individual patients, allowing precision medicine.

Mindshare Medical’s product has been designed to improve diagnostic efficacy and offer follow-up recommendations. It easily integrates with current picture archiving and communication systems (PACS), noted the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mindshare Medical added that RevealAI-Lung can minimise false-positives and the time to diagnosis. This is expected to help avoid unnecessary imaging procedures and biopsy in the case of certain patients.

In addition, the AI solution can potentially help in the treatment of lung cancer at an earlier stage.

Mindshare Medical CEO Michael Calhoun said: “We at Mindshare are very pleased to bring RevealAI to the European market as the first cleared CADx product. From radiology to thoracic surgery, there are broad implications, and we’re excited about delivering this benefit to help patients and help healthcare systems deliver care.”

Considered as the leading cause of death globally, lung cancer was responsible for 376,000 deaths in Europe in 2017. Mindshare expects RevealAI to boost lung cancer screening programmes across the continent.